Treatment of Hepatitis C Virus Infection with Alisporivir
OwnerClaudio Avila, Rafael Crabbeinventors
Life of this patent
Estimating the term…
Abstract
The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis C virus infection.
Claims12
Alisporivir for use in treatment of a Hepatitis C virus genotype 1 infected patient in combination with standard of care characterized in that
- (i) the patient is a relapser or a non-responder patient, and
- (ii) alisporivir is administered during an initial phase in an amount of about 600 mg, twice per day;
- followed by administering alisporivir during a second phase in an amount of about 600 to about 1000 mg once per day.
A method of treating of a Hepatitis C virus genotype 1 infected relapser or non-responder patient with alisporivir in combination with standard of care, the method comprising administering alisporivir during an initial phase in an amount of about 600 mg, twice per day for 7 days;
- followed by administering alisporivir during a second phase in an amount of about 600 to about 1000 mg once per day for up to 23, 47 or 71 weeks.
Use of alisporivir in the manufacture of a medicament for treatment of a Hepatitis C virus genotype 1 infected patient characterized in that
- (i) the patient is a relapser or a non-responder patient and
- (ii) alisporivir is administered during an initial phase in an amount of about 600 mg, twice per day for 7 days;
- followed by administering alisporivir during a second phase in an amount of about 600 to about 800 mg once per day for up to 23, 47 or 71 weeks
- and wherein alisporivir is administered in combination with standard of care throughout the initial and second phases.
A combination of alisporivir, and standard of care for use in treatment of a Hepatitis C virus genotype 1 infected relapser or non-responder patient characterized in that alisporivir is administered during an initial phase in an amount of about 600 mg, twice per day for 7 days;
- followed by administering alisporivir during a second phase in an amount of about 600 to about 800 mg once per day for up to 23, 47 or 71 weeks.
A therapeutic regimen comprising administering alisporivir during an initial phase in an amount of about 600 mg, twice per day for 7 days;
- followed by administering alisporivir during a second phase in an amount of about 600 to about 800 mg once per day for up to 23, 47 or 71 weeks and wherein alisporivir is administered in combination with standard of care throughout the initial and second phases.
Dependencies are inferred from the claim text.